MBRX

SEC filing MBRX Reports $12M Revenue, $3.4M Net Income, Announces $20B Buyback

4d ago

SEC filing MBRX Posts Updated Corporate Presentation, Furnishes Investor Materials on Company Website

7d ago

SEC filing MBRX Announces Acceptance of Annamycin Cardiac Safety Data Abstract for Poster Presentation at 2026 ASCO Annual Meeting, Highlights No Statistically Significant Change in LVEF, No Evidence of Drug-Induced Cardiotoxicity

10d ago

News Moleculin Biotech GAAP EPS of -$3.54 misses by $2.08

18d ago

SEC filing MBRX Reports Q1 2026 $8.3M Financing, 40% Remission Rate in AML Trial

18d ago

SEC filing MBRX Reports MIRACLE Trial CRc >40% (≈67% vs SOC), CR ~30%, 56/90 AML pts Enrolled, Unblinding Expected Q2 2026

20d ago

SEC filing MBRX Annamycin Extends Survival 60% in Metastatic Pancreatic Cancer Preclinical Models, Non-Cardiotoxic Anthracycline Shows Significant Tumor Reduction, Enhanced Tissue Accumulation vs Doxorubicin, Immune Cell Infiltration, Phase 2B/3 MIRACLE Trial Enrollment

40d ago

SEC filing MBRX Votes: Nasdaq Warrants 854K/211K/7K, Name Change 2.0M/83K/285K, Adjourn 616K/170K/287K

48d ago

SEC filing MBRX Hits 45 Subjects, 40% Remission Rate, Mid‑2026 Data Readout Imminent

71d ago

SEC filing MBRX Announces $120M Capital Raise, $0.85 EPS, 15% YoY Revenue Growth, $2.1B Market Cap

75d ago

SEC filing MBRX Reports $1.2M Revenue, $0.02 EPS, 40% CRc Rate in MIRACLE AML Trial, 45-Patient Unblinding Mid‑2026

75d ago

SEC filing MBRX Reports 40% Preliminary CRc Rate, 67% Blinded CR Improvement, 35% Veneto Failures, 45-Subject Q1 2026 Unblinding Milestone

104d ago

SEC filing MBRX Announces Japanese Patent Allowance for Annamycin

105d ago

SEC filing Submission of Matters to a Vote of Security Holders

116d ago

News Kent Imaging Responds to a Complaint Filed with the ITC Concerning SnapshotGLO® and Reaffirms Commitment to Clinical Innovation

134d ago

Scanner Unusual volume (z=7.8)

165d ago